

Eylea® (aflibercept) Injection



When requesting Eylea® (aflibercept), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial uses and meet the specific coverage guidelines for the covered indications.

FDA-approved indications

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)

Approved Off-label Compendial uses

- Neovascular glaucoma
- Retinopathy of prematurity
- Sickle Cell neovascularizations
- Choroidal neovascular conditions

Coverage Guidelines

For all approved indications the individual must meet the following criteria for approval:

- The drug is administered by or under the supervision of an ophthalmologist

Approval duration (initial and renewal): 12 months

Dosing Recommendations

- **Neovascular (Wet) Age-Related Macular Degeneration** -2mg by intravitreal injection every 4 weeks for the first 3 months, followed by 2mg via intravitreal injection once every 8 weeks.
- **Macular Edema Following Retinal Vein Occlusion-** 2mg by intravitreal injection once every 4 weeks
- **Diabetic Macular Edema and Diabetic Retinopathy (DR)** -2mg administered via intravitreal injection every 4 weeks for the first 5 doses followed by 2mg every 4 or 8 weeks.
- **For off-label uses (neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularizations, and choroidal neovascular conditions) –** 2mg or less given by intravitreal injection once every 4 weeks

References

1. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-related macular degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015. Accessed on October 29, 2018. Available at: www.aao.org/ppp.

2. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2017. Accessed on October 29, 2018. Available at: www.aao.org/ppp.
3. Eylea® injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; May 2019.
4. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
5. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
6. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
7. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.
8. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2008;115(10):1837-1846.